HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-6.99%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.69B
AUM Growth
+$1.69B
(+2.5%)
Cap. Flow
+$191M
Cap. Flow
% of AUM
11.32%
Top 10 Holdings %
Top 10 Hldgs %
60.09%
Holding
55
New
12
Increased
19
Reduced
5
Closed
17
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$94.7M |
| 2 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$90.4M |
| 3 |
DexCom
DXCM
|
$69.6M |
| 4 |
HCA Healthcare
HCA
|
$65.5M |
| 5 |
Edwards Lifesciences
EW
|
$64.3M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$112M |
| 2 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
$105M |
| 3 |
BCR
CR Bard Inc.
BCR
|
$89.2M |
| 4 |
Abbott
ABT
|
$74.5M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$59.4M |
Sector Composition
| 1 | Healthcare | 81.78% |
| 2 | Financials | 3.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$21B
| $160M | 9.06% | 1,500,000 +600,000 | +67% | +$64M |
|
|
2
Quest Diagnostics
DGX
$20.3B
| $132M | 7.49% | 1,850,000 +1,325,350 | +253% | +$94.7M |
|
|
3
DexCom
DXCM
$29.5B
| $121M | 6.83% | 1,775,000 +1,025,000 | +137% | +$69.6M |
|
4
Labcorp
LH
$23.1B
| $111M | 6.3% | 950,000 +150,000 | +19% | +$17.6M |
|
|
MNK
5
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $106M | 5.99% | 1,725,000 +1,475,610 | +592% | +$90.4M |
|
|
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
| $92.7M | 5.25% | 2,015,000 -285,000 | -12% | -$13.1M |
|
7
Universal Health Services
UHS
$11.6B
| $78M | 4.42% | 625,000 +258,610 | +71% | +$32.3M |
|
|
AKRX
8
DELISTED
Akorn, Inc.
AKRX
| $74.7M | 4.23% | 3,175,000 +1,175,000 | +59% | +$27.6M |
|
|
9
Edwards Lifesciences
EW
$47.8B
| $72.8M | 4.12% | 825,000 +729,240 | +762% | +$64.3M |
|
|
10
HCA Healthcare
HCA
$94.5B
| $66.3M | 3.76% | 850,000 +838,820 | +7,503% | +$65.5M |
|
|
AET
11
DELISTED
Aetna Inc
AET
| $56.2M | 3.18% | +500,000 | New | +$56.2M |
|
12
Thermo Fisher Scientific
TMO
$186B
| $53.1M | 3.01% | +375,000 | New | +$53.1M |
|
|
BCR
13
DELISTED
CR Bard Inc.
BCR
| $52.7M | 2.99% | 260,000 -440,000 | -63% | -$89.2M |
|
14
Pfizer
PFE
$141B
| $47.4M | 2.69% | 1,600,000 +29,870 | +2% | +$885K |
|
15
Encompass Health
EHC
$12.3B
| $41.4M | 2.35% | +1,100,000 | New | +$41.4M |
|
|
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
| $38.4M | 2.18% | 2,000,000 +475,000 | +31% | +$9.12M |
|
17
Humana
HUM
$36.5B
| $36.6M | 2.07% | +200,000 | New | +$36.6M |
|
18
Icon
ICLR
$13.8B
| $30.1M | 1.71% | 401,400 +1,400 | +0.4% | +$105K |
|
19
Neurocrine Biosciences
NBIX
$13.8B
| $28.7M | 1.62% | +725,000 | New | +$28.7M |
|
20
Waters Corp
WAT
$18B
| $26.1M | 1.48% | +198,039 | New | +$26.1M |
|
|
NVRO
21
DELISTED
NEVRO CORP.
NVRO
| $24.2M | 1.37% | +430,877 | New | +$24.2M |
|
22
Teva Pharmaceuticals
TEVA
$21.1B
| $22.5M | 1.27% | 419,760 -570,750 | -58% | -$30.5M |
|
|
PRAH
23
DELISTED
PRA Health Sciences, Inc.
PRAH
| $22.2M | 1.26% | +520,000 | New | +$22.2M |
|
24
Collegium Pharmaceutical
COLL
$1.22B
| $22.2M | 1.26% | 1,225,000 +200,000 | +20% | +$3.63M |
|
25
Zoetis
ZTS
$69.3B
| $21.3M | 1.21% | 479,820 +473,820 | +7,897% | +$21M |
|